Security
Spruce Biosciences, Inc. Common Stock · SPRB
SPRBNASDAQCommon stockCurrentCIK 1683553Updated Nov 10, 2026
SPRB price & chart
Loading TradingView…
NASDAQ:SPRB on TradingView ↗About the company
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. Spruce’s lead product candidate, tralesinidase alfa enzyme replacement therapy (“TA-ERT”), is in late-stage development for the treatment of mucopolysaccharidosis type IIIB (“MPS IIIB”), or Sanfilippo Syndrome Type B, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A - filed by CITADEL ADVISORS LLC regarding SPRUCE BIOSCIENCES, INC.
SCHEDULE 13G - filed by AWM Investment Company, Inc. regarding SPRUCE BIOSCIENCES, INC.
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A - filed by INTEGRATED CORE STRATEGIES (US) LLC regarding SPRUCE BIOSCIENCES, INC.
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 15,313,000Source | 65,102,000Source | 102,852,000Source | 21,820,000Source | 75,519,000Source | 56,166,000Source | 31,649,000Source | 87,539,000Source | 53,021,000Source | 45,209,000Source | 103,946,000Source | 85,648,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,669,000Source | 60,055,000Source | 96,295,000Source | 16,387,000Source | 69,683,000Source | 54,080,000Source | 25,615,000Source | 81,154,000Source | 48,906,000Source | 38,753,000Source | 96,339,000Source | 24,487,000Source |
| Assets, CurrentUSD | 14,516,000Source | 63,573,000Source | 101,154,000Source | 20,953,000Source | 73,912,000Source | 55,032,000Source | 30,576,000Source | 85,865,000Source | 52,112,000Source | 44,206,000Source | 102,183,000Source | 83,608,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | — | — | — | — | 1,400,000Source |
| Other Assets, NoncurrentUSD | 62,000Source | 531,000Source | 1,175,000Source | 64,000Source | 547,000Source | 539,000Source | 204,000Source | 553,000Source | 243,000Source | 69,000Source | 582,000Source | 640,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 9,927,000Source | 13,464,000Source | 19,122,000Source | 8,640,000Source | 16,350,000Source | 21,518,000Source | 16,325,000Source | 20,915,000Source | 10,505,000Source | 16,388,000Source | 27,437,000Source | 17,162,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 0Source | 4,000Source | 0Source | 0Source | 4,000Source | 0Source | 4,000Source | 4,000Source | 0Source | 4,000Source | 4,000Source | 3,000Source |
| Retained Earnings (Accumulated Deficit)USD | -274,588,000Source | -226,709,000Source | -317,729,000Source | -266,376,000Source | -218,038,000Source | -301,500,000Source | -264,309,000Source | -208,857,000Source | -289,234,000Source | -250,268,000Source | -197,232,000Source | -149,313,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -558,000Source |
| Stockholders' Equity Attributable to ParentUSD | 5,386,000Source | 51,638,000Source | 83,730,000Source | 13,180,000Source | 59,169,000Source | 34,648,000Source | 15,324,000Source | 66,624,000Source | 42,516,000Source | 28,821,000Source | 76,509,000Source | 68,486,000Source |
| Additional Paid in Capital, Common StockUSD | 279,974,000Source | 278,343,000Source | 401,459,000Source | 279,556,000Source | 277,203,000Source | 336,148,000Source | 279,629,000Source | 275,477,000Source | 331,750,000Source | 279,085,000Source | 273,737,000Source | 218,354,000Source |
| Liabilities and EquityUSD | 15,313,000Source | 65,102,000Source | 102,852,000Source | 21,820,000Source | 75,519,000Source | 56,166,000Source | 31,649,000Source | 87,539,000Source | 53,021,000Source | 45,209,000Source | 103,946,000Source | 85,648,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 9,427,000Source | 11,858,000Source | 10,963,000Source | 8,060,000Source | 14,285,000Source | 11,784,000Source | 15,666,000Source | 18,394,000Source | 10,086,000Source | 15,246,000Source | 24,465,000Source | 12,447,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | 317,000Source | 283,000Source | 251,000Source | 139,000Source |
| Accounts Payable, CurrentUSD | 1,386,000Source | 1,799,000Source | 1,209,000Source | 807,000Source | 682,000Source | 2,683,000Source | 1,879,000Source | 1,891,000Source | 943,000Source | 1,295,000Source | 3,332,000Source | 1,426,000Source |
| Operating Lease, Liability, NoncurrentUSD | 500,000Source | — | 245,000Source | 580,000Source | — | 332,000Source | 659,000Source | 950,000Source | 419,000Source | 736,000Source | 1,019,000Source | 1,261,000Source |
| Other Liabilities, NoncurrentUSD | 0Source | 273,000Source | — | 0Source | 262,000Source | — | 0Source | 250,000Source | 0Source | 282,000Source | 236,000Source | 161,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 7,502,000Source | 7,740,000Source | 7,254,000Source | 6,310,000Source | 10,683,000Source | 8,101,000Source | 12,442,000Source | — | 9,143,000Source | 12,329,000Source | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 10,700,000Source | 60,100,000Source | 96,300,000Source | 16,400,000Source | 69,700,000Source | 54,100,000Source | 25,600,000Source | 81,200,000Source | 48,900,000Source | 38,800,000Source | 96,300,000Source | 79,100,000Source |
| Deferred Revenue, CurrentUSD | — | 697,000Source | — | — | 1,298,000Source | — | — | 2,908,000Source | — | 0Source | 4,911,000Source | — |
| Long-term Debt, Current MaturitiesUSD | 539,000Source | 1,622,000Source | 2,500,000Source | 943,000Source | 1,622,000Source | 1,000,000Source | 1,345,000Source | 1,622,000Source | 0Source | 1,622,000Source | 1,622,000Source | 1,622,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 0Source | 524,000Source | 4,591,000Source | 0Source | 923,000Source | 5,464,000Source | 0Source | 1,321,000Source | 0Source | 124,000Source | 1,717,000Source | 3,293,000Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 54,590,000Source |
| Long-term Debt, Excluding Current Maturities | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -12,266,000Source | -14,041,000Source | -38,966,000Source | -53,036,000Source | -47,919,000Source | -46,180,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortizationUSD | — | — | — | — | — | — | 252,000Source | 6,000Source | 21,000Source | 46,000Source | 70,000Source | 74,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 689,000Source | 544,000Source | 2,574,000Source | 5,348,000Source | 4,622,000Source | 3,631,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,700,000Source | 584,000Source | -352,000Source | -2,037,000Source | 1,906,000Source | -1,397,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -8,732,000Source | -12,727,000Source | -33,327,000Source | -55,964,000Source | -33,275,000Source | -41,683,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -10,000Source | 0Source | — | 0Source | 55,777,000Source | 23,692,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 10,000Source | 0Source | — | 0Source | 7,000Source | 8,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 10,000Source | 0Source | 831,000Source | 246,000Source | 311,000Source | 40,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 13,916,000Source | -411,000Source | 43,481,000Source | -1,622,000Source | 49,140,000Source | -241,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | 0Source | 405,000Source | 2,057,000Source | 1,622,000Source | 1,622,000Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 10,704,000Source | 60,090,000Source | 96,331,000Source | 16,422,000Source | 54,116,000Source | 25,650,000Source | 48,942,000Source | 38,788,000Source | 96,374,000Source | 24,732,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 68,000Source | 225,000Source | 369,000Source | 266,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 415,000Source | 1,140,000Source | 871,000Source | -77,000Source | 689,000Source | 544,000Source | 2,574,000Source | 5,348,000Source | 4,622,000Source | 3,631,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 10,700,000Source | 60,100,000Source | 96,300,000Source | 16,400,000Source | 54,100,000Source | 25,600,000Source | 48,900,000Source | 38,800,000Source | 96,300,000Source | 79,100,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | -39,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 750,000Source |
| General and Administrative ExpenseUSD | — | — | 3,218,000Source | 3,456,000Source | 4,349,000Source | 3,122,000Source | 4,412,000Source | 3,655,000Source | 16,991,000Source | 14,644,000Source | 12,650,000Source | 12,085,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,212,000Source | -8,671,000Source | -16,229,000Source | -2,067,000Source | -12,266,000Source | -14,041,000Source | -38,966,000Source | -53,036,000Source | -47,919,000Source | -46,180,000Source |
| Operating ExpensesUSD | — | — | 8,229,000Source | 10,010,000Source | 16,512,000Source | 2,692,000Source | 11,987,000Source | 14,492,000Source | 36,513,000Source | 61,062,000Source | 62,082,000Source | 47,283,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | — | 0Source | 11,881,000Source | 36,800,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | 14,146,000Source | 0Source | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 0Source | 5,000Source | 180,000Source | 1,000Source | 2,000Source |
| Other Nonoperating Income (Expense) | — | — | — | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 602,000Source | — | 0Source | — | 0Source | 0Source | 4,911,000Source | 10,089,000Source | — |
| Operating Income (Loss)USD | — | — | -8,229,000Source | -9,408,000Source | -16,512,000Source | -2,692,000Source | -11,987,000Source | -14,492,000Source | -36,513,000Source | -56,151,000Source | -51,993,000Source | -47,283,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,212,000Source | -8,671,000Source | -16,229,000Source | -2,067,000Source | -12,266,000Source | -14,041,000Source | -38,966,000Source | -53,036,000Source | -47,919,000Source | -46,180,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -14.58Source | -15.75Source | -6.68Source | -3.5Source | -8.94Source | -23.95Source | -50.83Source | -1.29Source | -1.24Source | -1.96Source |
| Earnings Per Share, DilutedUSD per share | — | — | -14.58Source | -15.75Source | -6.68Source | -3.5Source | -8.94Source | -23.95Source | -50.83Source | -1.29Source | -1.24Source | -1.96Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 563,066Source | 550,645Source | 2,431,075Source | 591,137Source | 1,372,084Source | 586,142Source | 766,598Source | 41,264,948Source | 38,510,220Source | 23,527,116Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 563,066Source | 550,645Source | 2,431,075Source | 591,137Source | 1,372,084Source | 586,142Source | 766,598Source | 41,264,948Source | 38,510,220Source | 23,527,116Source |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 252,000Source | 6,000Source | 21,000Source | 46,000Source | 70,000Source | 74,000Source |
| General and Administrative ExpenseUSD | — | — | 3,218,000Source | 3,456,000Source | 4,349,000Source | 3,122,000Source | 4,412,000Source | 3,655,000Source | 16,991,000Source | 14,644,000Source | 12,650,000Source | 12,085,000Source |
| Interest and Other IncomeUSD | — | — | 36,000Source | 808,000Source | 765,000Source | 193,000Source | 486,000Source | 329,000Source | 1,137,000Source | 3,422,000Source | 4,557,000Source | 1,523,000Source |
| Interest ExpenseUSD | — | — | 19,000Source | 71,000Source | 1,097,000Source | 29,000Source | 674,000Source | 36,000Source | 90,000Source | 307,000Source | 483,000Source | 420,000Source |
| Operating ExpensesUSD | — | — | 8,229,000Source | 10,010,000Source | 16,512,000Source | 2,692,000Source | 11,987,000Source | 14,492,000Source | 36,513,000Source | 61,062,000Source | 62,082,000Source | 47,283,000Source |
| Research and Development ExpenseUSD | — | — | 5,011,000Source | 6,554,000Source | 12,163,000Source | -430,000Source | 7,575,000Source | 10,837,000Source | 19,522,000Source | 46,418,000Source | 49,432,000Source | 35,198,000Source |
| Other Nonoperating Income (Expense) | — | — | — | —Source | — | — | — | — | — | — | — | — |
Filing attachments
sprb-ex4_1.htm · 10-Q · 2026-11-09
Exhibit 4.1 FIRST AMENDMENT TO WARRANT TO PURCHASE SHARES OF COMMON STOCK THIS FIRST AMENDMENT TO WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant Amendment”) is entered into as of November 6, 2026, by and between AVENUE VENTURE OPPORTUNITIES FUND II, L.P., a Delaware limited partnership (“Holder”), and SPRUCE BIOSCIENCES, INC., a Delaware corporation (the “Company”). RECITALS A. WHEREAS, the Company issued to Holder that certain Warrant to Purchase Shares of Common Stock dated as …
Read attachment ↗sprb-ex4_2.htm · 10-Q · 2026-11-09
Exhibit 4.2 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF (A) SUCH REGISTRATION, (B) AN OPINION OF COUNSEL IN A FORM REASONABLY ACCEPTABLE TO COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED D…
Read attachment ↗sprb-ex99_1.htm · 8-K · 2026-11-09
Exhibit 99.1 Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates Biologics License Application (“BLA”) Submission for Tralesinidase Alfa Enzyme Replacement Therapy (“TA-ERT”) for the Treatment of MPS IIIB Remains on Track for December 2026 Amended Avenue Loan Agreement to Increase Tranche 2 Availability to $15 Million and Extend Interest-Only Period Announced Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences South San Francis…
Read attachment ↗sprb-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 sprb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Biologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026 TrAnsform Confirmatory Study Required for Potential FDA Accelerated Approval of TA-ERT Expected to Initiate in the Fourth Quarter of 2026 Strengthened Leadership Team with the Appointments of Adrian Quartel, M.D., FFPM, as …
Read attachment ↗sprb-ex99_1.htm · S-8 · 2026-05-13
Exhibit 99.1 Spruce Biosciences, Inc. 2026 Inducement Plan Adopted by the Board of Directors: MAY 11, 2026 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for “employment inducement grants” under Nasdaq Listing Rule 5635(c)(4) and the related guidance under Nasdaq IM-5635-1 (together with any analogous rules or guidance effective after the date hereof, the “Inducement Award Rules”). …
Read attachment ↗sprb-ex99_2.htm · S-8 · 2026-05-13
Exhibit 99.2 Spruce Biosciences, Inc. RSU Award Grant Notice(2026 Inducement Plan) Spruce Biosciences, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Spruce Biosciences, Inc. 2026 Inducement Plan (the “Plan”) and the Award Agreement (the “Agreement”), which ar…
Read attachment ↗